Dose response of pegfilgrastim in Japanese breast cancer patients receiving six cycles of docetaxel, doxorubicin, and cyclophosphamide therapy: a randomized controlled trial.

Item

http://www.wikidata.org/entity/Q36004954

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Dose response of pegfilgrastim ...... a randomized controlled trial.

@ast

Dose response of pegfilgrastim ...... a randomized controlled trial.

@en

type

Item

label

Dose response of pegfilgrastim ...... a randomized controlled trial.

@ast

Dose response of pegfilgrastim ...... a randomized controlled trial.

@en

prefLabel

Dose response of pegfilgrastim ...... a randomized controlled trial.

@ast

Dose response of pegfilgrastim ...... a randomized controlled trial.

@en

P1476

Dose response of pegfilgrastim ...... a randomized controlled trial.

@en

P2093

Kazuo Tamura

http://www.w3.org/2001/XMLSchema#string

Norikazu Masuda

http://www.w3.org/2001/XMLSchema#string

Ryutaro Shimazaki

http://www.w3.org/2001/XMLSchema#string

Seigo Nakamura

http://www.w3.org/2001/XMLSchema#string

Yoshinori Ito

http://www.w3.org/2001/XMLSchema#string

Yutaka Tokuda

http://www.w3.org/2001/XMLSchema#string

P2860

2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline.

First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study.

2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours.

Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review.

Relative dose intensity of chemotherapy and its impact on outcomes in patients with early breast cancer or aggressive lymphoma.

Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colo

Optimal delivery of anthracycline-based chemotherapy in the adjuvant setting improves outcome of breast cancer patients.

Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer.

Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer.

A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy.

P2888

s00520-015-2654-4

P304

2891-2898

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00520-015-2654-4

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-03-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

273153631

http://www.w3.org/2001/XMLSchema#string

P698

25733000

http://www.w3.org/2001/XMLSchema#string

P932

4552775

http://www.w3.org/2001/XMLSchema#string